Inactive Instrument

Medicure Inc Stock Toronto S.E.

Equities

MPH

CA58469E4085

Biotechnology & Medical Research

Sales 2022 23.06M 16.87M Sales 2023 21.69M 15.87M Capitalization 14.61M 10.69M
Net income 2022 1M 731K Net income 2023 - 0 EV / Sales 2022 0.28 x
Net cash position 2022 4.01M 2.93M Net cash position 2023 5.82M 4.26M EV / Sales 2023 0.4 x
P/E ratio 2022
7.71 x
P/E ratio 2023
-15.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 73.01%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 76 97-09-14
Director of Finance/CFO - 22-05-31
President - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 90 00-02-27
Director/Board Member 68 05-11-28
Chief Executive Officer 76 97-09-14
More insiders
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
More about the company